Skip to main content
Glama

Openparliament Ca

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the annotations (readOnly, openWorld, idempotent, non-destructive), the description discloses cascading internal lookups, graceful degradation when LEI/FIGI sources fail, explicit `unresolved` reporting, and a `figi_candidates` behavior for ambiguous matches. This is rich behavioral context that annotations alone do not provide, and it does not contradict them.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long and information-dense, but each sentence adds value: usage directive, supported types, enrichment behavior, failure mode, and param hints. It is front-loaded with the purpose and 'Use FIRST' instruction. Slightly sprawling in the FIGI parenthetical, but not wasteful.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries the burden of explaining return values, and it does so thoroughly: labelled identifier sources, explicit `unresolved` entries, `figi_candidates` for ambiguous instrument matches, ownership hierarchy, and the drug-type return format including citation link. Nothing an agent needs to call this correctly is missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema already describes both parameters, but the description adds crucial semantics: for `company`, it lists accepted forms (ticker, CIK, ISIN, name) and explains ISIN-to-LEI mapping; for `value`, it gives the 'ENTITY NAME ONLY' rule with a concrete counterexample showing why trailing security-class words fail. This meaningfully exceeds the schema descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description uses a specific verb ('resolve') and resource (user-spoken names to canonical/official identifiers), and clearly distinguishes the tool from siblings by framing it as the prerequisite step: it produces the identifiers other tools require as input. The supported types and example phrasings make the scope unmistakable.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives an explicit directive ('Use FIRST whenever you have a name but need an ID') and provides numerous example queries that trigger this tool. It does not name specific sibling tools as alternatives for post-resolution steps, so the when-not-to-use guidance is only implied rather than explicit.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Openparliament Ca toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.1/5.0
Disambiguation2/5

The tool set mixes two distinct domains: 8 Canadian Parliament tools and 30 Pipeworx data tools. Within each domain, tools are somewhat distinct, but the overall mix creates confusion as agents cannot tell if a tool is for parliament or general data lookup.

Naming Consistency2/5

OpenParliament tools follow a consistent verb_noun pattern (list_*, get_*), but Pipeworx tools use varied conventions (e.g., 'remember', 'discover_tools', 'ask_pipeworx'). The lack of a unified naming scheme across the set reduces predictability.

Tool Count2/5

38 tools is excessive for a Canadian Parliament server. The core parliament tools (8) are well-scoped, but the addition of 30 unrelated Pipeworx tools makes the count bloated and inappropriate for the stated domain.

Completeness1/5

For the Canadian Parliament domain, coverage is adequate but lacks topic search and detailed legislative history. However, the server is dominated by Pipeworx tools, which are out of scope, making the overall surface severely incomplete for the implied purpose.

Resources